ProQR Therapeutics (PRQR) Accounts Payables (2021 - 2025)

ProQR Therapeutics (PRQR) has disclosed Accounts Payables for 5 consecutive years, with $346885.0 as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 1928.86% to $346885.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $346885.0 through Dec 2025, up 1928.86% year-over-year, with the annual reading at $346885.0 for FY2025, 1928.86% up from the prior year.
  • Accounts Payables hit $346885.0 in Q4 2025 for ProQR Therapeutics, up from $17097.5 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.7 million in Q4 2023 to a low of $17097.5 in Q4 2024.
  • Historically, Accounts Payables has averaged $528088.3 across 5 years, with a median of $346885.0 in 2025.
  • Biggest five-year swings in Accounts Payables: crashed 98.97% in 2024 and later soared 1928.86% in 2025.
  • Year by year, Accounts Payables stood at $218498.5 in 2021, then soared by 83.04% to $399937.0 in 2022, then skyrocketed by 314.57% to $1.7 million in 2023, then plummeted by 98.97% to $17097.5 in 2024, then skyrocketed by 1928.86% to $346885.0 in 2025.
  • Business Quant data shows Accounts Payables for PRQR at $346885.0 in Q4 2025, $17097.5 in Q4 2024, and $1.7 million in Q4 2023.